UBS Group Issues Positive Forecast for Encompass Health (NYSE:EHC) Stock Price

Key Points

• UBS Group raised its price target for Encompass Health (NYSE:EHC) from $140.00 to $150.00, indicating a potential upside of 20.40% from the previous close, and maintains a "buy" rating for the stock.
• Encompass Health recently posted earnings of $1.40 per share for the quarter, exceeding analysts' expectations of $1.20, with revenues of $1.46 billion, representing a year-over-year increase of 12.0%.
• Institutional investors hold approximately 97.25% of Encompass Health's stock, highlighting significant interest from larger investment firms.

Encompass Health (NYSE:EHC - Get Free Report) had its price target increased by equities research analysts at UBS Group from $140.00 to $150.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's target price indicates a potential upside of 20.40% from the company's previous close.

A number of other research firms have also recently commented on EHC. KeyCorp raised their target price on Encompass Health from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Wall Street Zen cut Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Bank of America lifted their price objective on Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday, September 10th. Truist Financial lifted their price objective on Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Finally, Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective for the company in a research note on Thursday, June 5th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $139.86.

Encompass Health Trading Down 1.9%

NYSE EHC opened at $124.59 on Thursday. Encompass Health has a fifty-two week low of $87.85 and a fifty-two week high of $127.86. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a 50 day simple moving average of $120.61 and a two-hundred day simple moving average of $115.19. The stock has a market cap of $12.55 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 2.22 and a beta of 0.93.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.20. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%.The business had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter last year, the business posted $1.11 EPS. The business's revenue was up 12.0% on a year-over-year basis. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. On average, analysts forecast that Encompass Health will post 4.8 earnings per share for the current year.

Insider Activity at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of Encompass Health stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the sale, the executive vice president owned 18,846 shares of the company's stock, valued at approximately $2,329,177.14. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.00% of the company's stock.

Institutional Trading of Encompass Health

Several large investors have recently modified their holdings of EHC. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Encompass Health by 46.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 19,204 shares of the company's stock worth $1,774,000 after acquiring an additional 6,053 shares during the period. GAMMA Investing LLC grew its holdings in shares of Encompass Health by 12,207.6% in the first quarter. GAMMA Investing LLC now owns 239,628 shares of the company's stock worth $24,270,000 after acquiring an additional 237,681 shares during the period. Parallel Advisors LLC grew its holdings in shares of Encompass Health by 25.0% in the first quarter. Parallel Advisors LLC now owns 2,319 shares of the company's stock worth $235,000 after acquiring an additional 464 shares during the period. NBC Securities Inc. grew its holdings in shares of Encompass Health by 140,033.3% in the first quarter. NBC Securities Inc. now owns 4,204 shares of the company's stock worth $425,000 after acquiring an additional 4,201 shares during the period. Finally, Merit Financial Group LLC grew its holdings in shares of Encompass Health by 4.1% in the first quarter. Merit Financial Group LLC now owns 4,220 shares of the company's stock worth $427,000 after acquiring an additional 166 shares during the period. Institutional investors own 97.25% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.